Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Subject and Investigator Blinded, Placebo-controlled Study to Demonstrate the Anti-inflammatory Effect of Fevipiprant (QAW039) in Moderate to Severe Asthma Patients With High Sputum and Blood Eosinophils.

Next Previous
X
Search
Trial Profile

Randomized, Subject and Investigator Blinded, Placebo-controlled Study to Demonstrate the Anti-inflammatory Effect of Fevipiprant (QAW039) in Moderate to Severe Asthma Patients With High Sputum and Blood Eosinophils.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 30 Jul 2022 This trial has been discontinued in Germany (Date of the global end of the trial : 26-Oct-2020), according to European Clinical Trials Database record.
    • 12 May 2020 Status changed from recruiting to withdrawn prior to enrolment.
    • 19 Jan 2020 This trial has been Discontinued in Spain (end date: 2019-12-16)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top